Weltelmi 80mg Tablet contains Telmisartan, an angiotensin II receptor antagonist primarily used to manage hypertension and reduce cardiovascular risk. By selectively blocking the binding of angiotensin II to the AT1 receptor, Telmisartan promotes vasodilation, decreases aldosterone secretion, and reduces sodium and water retention, thereby lowering blood pressure effectively. This antihypertensive agent is indicated for the treatment of essential hypertension, alone or in combination with other antihypertensive agents, and for cardiovascular risk reduction in patients at high risk of myocardial infarction, stroke, or death from cardiovascular causes. Weltelmi 80mg is well-tolerated, with a favorable safety profile, and is administered orally once daily, providing sustained blood pressure control. Common adverse effects may include dizziness, headache, and fatigue, while serious side effects are rare but may involve renal impairment or hyperkalemia, necessitating periodic monitoring of renal function and electrolytes during therapy. It is contraindicated in patients with hypersensitivity to Telmisartan or its components and should be used cautiously in patients with severe hepatic impairment or bilateral renal artery stenosis. Weltelmi 80mg should not be co-administered with aliskiren in diabetic patients or those with renal impairment. Patient adherence to prescribed dosage and regular follow-up are essential for optimal therapeutic outcomes.